Reagent: HIV-1 NL4-3 Infectious Molecular Clone (pNL4-3)

Catalog Number: 114

Lot Number: 140136

Release Category: C

Provided: 5 μg of purified DNA stabilized in DNASTABLE PLUS and dried

Cloning Vector: pUC18
Ampicillin resistant

Cloning Site: The 5’ Smal-EcoRI fragment of proviral NY5 (5’ SmaI in flanking sequences to 3’ EcoRI) and the 3’ fragment of proviral LAV (5’ EcoRI to 3’ NruI in flanking sequences) were blunt-end cloned into pUC18 at the PvuII site after removal of polylinker sites.

GenBank: AF324493

Host Strain: HB101

Description: Full-length, replication and infection competent chimeric DNA.

Special Characteristics: Upon transfection this clone directed the production of infectious virus particles in a wide variety of cells. The progeny, infectious virions, were synthesized in mouse, mink, monkey, and several non-T cell lines, indicating the absence of any intracellular obstacle to viral RNA or protein production or assembly. Source of provirus: NY5 (5’) and LAV (3’) cloned directly from genomic DNA.

Plasmid map and sequence file lot 140136
Contributor provided sequence information

This reagent is currently being provided as purified DNA stabilized in DNASTABLE PLUS and dried. Please see the notice for additional information and the protocol for reconstitution.
Recommended Storage: Keep the reagent at room temperature in a dry storage cabinet or in a moisture barrier bag.

Contributor: Dr. Malcolm Martin.


NOTE: Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 NL4-3 Infectious Molecular Clone (pNL4-3) from Dr. Malcolm Martin." Also include the reference cited above in any publications. Scientists at for-profit institutions or who intend commercial use of this reagent must contact the NIH Office of Technology Transfer at NIAID, Email: NIAIDAIDSReagent@niaid.nih.gov, before the reagent can be released. Please specify the name and a description of the intended use of the reagent.

Last Updated: March 16, 2018